Seelos Therapeutics Announced Topline Data From The SLS-002 Phase 2 Study Demonstrating Clinically Meaningful Treatment Effects Across Multiple Endpoints, Well-tolerated Safety Profile For Acute Suicidal Ideation And Behavior In Major Depressive Disorder
Portfolio Pulse from Benzinga Newsdesk
Seelos Therapeutics has announced topline data from the SLS-002 Phase 2 study, showing clinically meaningful treatment effects across multiple endpoints. The study also demonstrated a well-tolerated safety profile for acute suicidal ideation and behavior in major depressive disorder.
September 20, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The positive topline data from Seelos Therapeutics' SLS-002 Phase 2 study could potentially boost the company's stock in the short term.
Positive clinical trial results often lead to an increase in the stock price of pharmaceutical companies. The announcement of positive topline data from the SLS-002 Phase 2 study, which shows promising treatment effects and a good safety profile, could therefore lead to a short-term increase in the price of Seelos Therapeutics' stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100